Fig. 2

Veverimer Effects on Serum Bicarbonate. A The top line shows the composite endpoint at treatment week 52. The two lower lines depict each component of the primary endpoint (percentage of patients who had a ≥ 4 mmol/L increase or normalization of serum bicarbonate at week 52). P-values are for the difference in proportions between the veverimer and placebo groups. B Change in serum bicarbonate from baseline to week 52. C Serum bicarbonate levels over time. The baseline serum bicarbonate was 17.2 (0.2) mmol/L and 17.3 (0.2) mmol/L in the veverimer and placebo groups, respectively. LS, least squares; SE, standard error